MYELOF
MCID: MYL005
MIFTS: 70

Myelofibrosis (MYELOF)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Myelofibrosis

MalaCards integrated aliases for Myelofibrosis:

Name: Myelofibrosis 56 12 74 52 73 36 29 54 6 15 37 39 71
Primary Myelofibrosis 12 52 25 58 54 43 17 71
Agnogenic Myeloid Metaplasia 12 52 25 58 73 54
Myelofibrosis with Myeloid Metaplasia 25 58 73 29 6
Idiopathic Myelofibrosis 52 25 58 73 54
Myeloid Metaplasia 52 25 54 71
Osteomyelofibrosis 58 71 32
Myelofibrosis with Myeloid Metaplasia, Somatic 56 13
Megakaryocytic Myelosclerosis 12 71
Myelosclerosis 12 73
Agnogenic Myeloid Metaplasia with Myelofibrosis 73
Myelosclerosis with Myeloid Metaplasia 73
Chronic Idiopathic Myelofibrosis 25
Myelofibrosis, Somatic 56
Bone Marrow Fibrosis 12
Aleukemic Myelosis 12
Myelof 73
Ammm 73
Mmm 73

Characteristics:

Orphanet epidemiological data:

58
primary myelofibrosis
Prevalence: 1-9/100000 (Europe); Age of onset: Adult;

OMIM:

56
Inheritance:
somatic mutation

Miscellaneous:
onset first weeks of life


HPO:

31

Classifications:

Orphanet: 58  
Rare haematological diseases


Summaries for Myelofibrosis

Genetics Home Reference : 25 Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis. Initially, most people with primary myelofibrosis have no signs or symptoms. Eventually, fibrosis can lead to a reduction in the number of red blood cells, white blood cells, and platelets. A shortage of red blood cells (anemia) often causes extreme tiredness (fatigue) or shortness of breath. A loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising. Because blood cell formation (hematopoiesis) in the bone marrow is disrupted, other organs such as the spleen or liver may begin to produce blood cells. This process, called extramedullary hematopoiesis, often leads to an enlarged spleen (splenomegaly) or an enlarged liver (hepatomegaly). People with splenomegaly may feel pain or fullness in the abdomen, especially below the ribs on the left side. Other common signs and symptoms of primary myelofibrosis include fever, night sweats, and bone pain. Primary myelofibrosis is most commonly diagnosed in people aged 50 to 80 but can occur at any age.

MalaCards based summary : Myelofibrosis, also known as primary myelofibrosis, is related to gray platelet syndrome and myeloproliferative neoplasm. An important gene associated with Myelofibrosis is MPL (MPL Proto-Oncogene, Thrombopoietin Receptor), and among its related pathways/superpathways are JAK-STAT signaling pathway and TGF-Beta Pathway. The drugs Parathyroid hormone and Panobinostat have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and bone marrow, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.

NIH Rare Diseases : 52 Myelofibrosis is a disorder of the spongy tissue inside the bone (bone marrow) that contains the stem cells that will form blood cells . In myelofibrosis, the bone marrow is replaced by fibrous (scar) tissue. When the bone marrow is scarred, it cannot make enough blood cells. This leads to anemia , weakness, fatigue, and often, swelling of the liver and spleen. The disorder occurs when blood stem cells develop somatic mutations in the JAK2 , MPL , CALR , and TET2 genes . Other genes may also be involved. The disorder is generally not inherited because this type of mutation does not affect the reproductive cells (sperm and egg) only certain cells of the body (somatic). Although myelofibrosis can occur at any age, it typically develops after the age of 50 years. In most cases, myelofibrosis gets progressively worse. Treatment is aimed at relieving signs and symptoms and may include medications, blood transfusions, chemotherapy , radiation therapy , and surgery. Bone marrow or stem cell transplant may improve symptoms, and may cure the disease.

KEGG : 36 Myelofibrosis (MF), one of the three classic Philadelphia-chromosome-negative myeloproliferative neoplasms (MPNs), is characterized by symptoms mainly derived from anemia and splenomegaly and constitutional symptoms and associated with a median survival around 6 years. Most MPN patients harbor an acquired mutation in the hemopoietic cells, the V617F mutation, located in the pseudokinase domain of the JAK2 gene. This mutation results in a gain of function, i.e., in the constitutive activation of the JAK-STAT pathway, which plays an important role in the proliferation, differentiation, and survival of the hemopoietic cells, as well as in the immune function. Besides, a minority of patients with MF (most of them negative for the JAK2 mutation) harbor other JAK-STAT-activating mutation, the MPL mutation, in the gene of the receptor of the thrombopoietin. Recently, mutations in the CALR gene have been described in 86% of cases with primary MF that are negative for JAK2 or MPL mutations. CALR mutation also showed cytokine independent growth of cells due to activation of STAT5 involved with the JAK-STAT pathway but its exact role in MPN remains to be clarified.

UniProtKB/Swiss-Prot : 73 Myelofibrosis: A disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
Myelofibrosis with myeloid metaplasia: A chronic myeloproliferative disorder characterized by replacement of the bone marrow by fibrous tissue, extramedullary hematopoiesis, anemia, leukoerythroblastosis and hepatosplenomegaly.

Wikipedia : 74 Primary myelofibrosis is a relatively rare bone marrow / blood cancer. It is currently classified as a... more...

More information from OMIM: 254450

Related Diseases for Myelofibrosis

Diseases related to Myelofibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 620, show less)
# Related Disease Score Top Affiliating Genes
1 gray platelet syndrome 33.8 THPO MPIG6B GATA1
2 myeloproliferative neoplasm 33.5 THPO TET2 SH2B3 MPL KIT JAK2
3 polycythemia vera 33.5 THPO TET2 MPL KIT JAK2 HMGA2
4 megakaryocytic leukemia 33.1 THPO JAK2 GATA1
5 essential thrombocythemia 32.9 THPO TET2 SRC SH2B3 MPL MIR223
6 splenomegaly 32.7 MPL JAK2 EPO
7 polycythemia 32.5 THPO TET2 SH2B3 MPL JAK2 EPO
8 pancytopenia 32.2 THPO MPL MPIG6B KIT EPO
9 thrombocytosis 32.2 THPO TET2 SH2B3 MPL JAK2 EPO
10 thrombocytopenia 32.2 THPO SRC MPL MPIG6B JAK2 GATA1
11 leukemia 31.9 THPO TET2 MPL KIT JAK2 CDKN2B-AS1
12 acute leukemia 31.9 THPO MPL KIT JAK2 GATA1 EPO
13 deficiency anemia 31.8 THPO KIT JAK2 GATA1 EPO BMP6
14 neutropenia 31.8 THPO MPL GATA1 EPO CD177
15 myelodysplastic syndrome 31.8 THPO TET2 SH2B3 MPL MEG3 KIT
16 chronic myelomonocytic leukemia 31.5 TET2 MPL KIT JAK2 CALR
17 myeloma, multiple 31.5 SRC MEG3 KIT JAK2 FGF2 EPO
18 refractory anemia 31.5 TET2 MPL EPO
19 mastocytosis 31.4 TET2 KIT JAK2
20 systemic mastocytosis 31.4 TET2 KIT JAK2
21 aplastic anemia 31.3 THPO TET2 MPL GATA1 FGF2 EPO
22 hemoglobinuria 31.3 THPO MPL EPO
23 budd-chiari syndrome 31.1 MPL JAK2 CALR
24 acquired polycythemia 31.0 MPL JAK2 EPO
25 leukemia, chronic myeloid 31.0 THPO SRC MPL MIR223 MEG3 KIT
26 portal vein thrombosis 31.0 MPL JAK2 CALR
27 hypersplenism 31.0 THPO EPO BMP6
28 leukemia, acute myeloid 30.9 WT1-AS THPO TET2 SRC MPL MIR223
29 myelophthisic anemia 30.9 SH2B3 MPL JAK2 EPO CALR
30 chronic neutrophilic leukemia 30.9 TET2 JAK2 CALR
31 blood platelet disease 30.8 THPO MPL KIT JAK2 EPO
32 chronic eosinophilic leukemia 30.8 TET2 KIT JAK2
33 leukemia, acute lymphoblastic 30.7 THPO MPL MIR223 KIT JAK2 GATA1
34 thrombocythemia 1 30.7 THPO SH2B3 MPL CALR
35 splenic sequestration 30.6 THPO MPL EPO
36 leukemia, chronic lymphocytic 30.6 THPO TET2 SRC MIR223 KIT JAK2
37 erythrocytosis, familial, 1 30.6 SH2B3 JAK2 EPO
38 erythroleukemia, familial 30.6 GATA1 EPO
39 myelodysplastic/myeloproliferative neoplasm 30.6 TET2 KIT JAK2
40 chronic leukemia 30.6 TET2 KIT JAK2
41 diamond-blackfan anemia 30.6 THPO MPL JAK2 GATA1 EPO
42 hematologic cancer 30.4 THPO MPL MIR223 MIR146B KIT JAK2
43 glioma 30.3 MIR146B MEG3 FGF2 CDKN2B-AS1
44 acute promyelocytic leukemia 30.2 THPO SRC MIR223 GATA1 CALR
45 diabetes mellitus 29.5 SH2B3 MIR223 MEG3 FGF2 EPO CDKN2B-AS1
46 ovarian cancer 29.3 SRC MIR223 MIR146B MEG3 KIT JAK2
47 acute panmyelosis with myelofibrosis 12.8
48 thrombocytopenia, anemia, and myelofibrosis 12.6
49 cellular phase chronic idiopathic myelofibrosis 12.3
50 thrombocytopenia 6 12.1
51 neutropenia, severe congenital, 5, autosomal recessive 11.5
52 specific granule deficiency 2 11.3
53 bleeding disorder, platelet-type, 17 11.2
54 amegakaryocytic thrombocytopenia, congenital 10.8 THPO MPL JAK2 GATA1
55 sm-ahnmd 10.8 TET2 KIT JAK2
56 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.8 KIT JAK2 EPO
57 blood coagulation disease 10.7 THPO MPL KIT JAK2 EPO
58 systemic mastocytosis with associated hematologic neoplasm 10.7 TET2 KIT
59 thrombocytopenia 3 10.7 THPO MPL
60 juvenile nasopharyngeal angiofibroma 10.7 KIT FGF2 BMP6
61 myeloproliferative syndrome, transient 10.7 THPO MPL GATA1
62 combined t cell and b cell immunodeficiency 10.7 THPO SRC KIT JAK2 FGF2
63 myeloid leukemia 10.7
64 bone marrow cancer 10.7 THPO TET2 MPL KIT JAK2 GATA1
65 deep leiomyoma 10.7 KIT CD177
66 extracutaneous mastocytoma 10.7 TET2 KIT
67 retinitis pigmentosa and erythrocytic microcytosis 10.7 JAK2 EPO
68 dyskeratosis congenita, autosomal dominant 6 10.7 THPO MPL
69 myoma 10.7 KIT HMGA2 EPO
70 autoimmune hepatitis type 1 10.6 SH2B3 BMP6
71 endosteal hyperostosis, autosomal dominant 10.6
72 dedifferentiated liposarcoma 10.6 KIT HMGA2 CALR
73 inflammatory bowel disease 27 10.6 GATA1 EPO
74 thrombocytopenia 1 10.6 THPO GATA1
75 acquired thrombocytopenia 10.6 THPO MPL
76 pancreatic adenocarcinoma 10.6 SRC KIT JAK2 FGF2 BMP6
77 graft-versus-host disease 10.5
78 mucinous stomach adenocarcinoma 10.5 SRC KIT
79 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.5
80 chromosomal triplication 10.5
81 portal hypertension 10.5
82 dupuytren contracture 10.5 FGF2 BMP6
83 wilms tumor 1 10.5 WT1-AS MEG3 KIT GATA1
84 core binding factor acute myeloid leukemia 10.4 KIT JAK2
85 systemic lupus erythematosus 10.4
86 lupus erythematosus 10.4
87 acute graft versus host disease 10.4
88 lymphoma 10.4
89 pulmonary hypertension 10.4
90 hemosiderosis 10.3
91 rare hereditary hemochromatosis 10.3
92 autoimmune disease 10.3
93 rickets 10.3
94 melanoma, cutaneous malignant 10 10.3
95 melanoma 10.3
96 myeloid sarcoma 10.3
97 thrombosis 10.3
98 hemolytic anemia 10.3
99 thrombophilia due to thrombin defect 10.3
100 purpura 10.3
101 severe combined immunodeficiency 10.3
102 varicose veins 10.2
103 pyoderma 10.2
104 pyoderma gangrenosum 10.2
105 hypereosinophilic syndrome 10.2
106 47,xyy 10.2
107 primary hypertrophic osteoarthropathy 10.2
108 trisomy 1q 10.2
109 benign mesothelioma 10.2
110 malignant pleural mesothelioma 10.2
111 idiopathic spinal cord herniation 10.2
112 cebpa-associated familial acute myeloid leukemia 10.2 KIT JAK2
113 fibrosis of extraocular muscles, congenital, 1 10.2
114 sarcoma 10.2
115 spindle cell sarcoma 10.2
116 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
117 respiratory failure 10.2
118 hairy cell leukemia 10.2
119 chronic graft versus host disease 10.2
120 thrombocytopenic purpura, autoimmune 10.1
121 anemia, autoimmune hemolytic 10.1
122 thalassemia 10.1
123 esophageal varix 10.1
124 hyperparathyroidism 10.1
125 iron metabolism disease 10.1
126 liver cirrhosis 10.1
127 peripheral nervous system disease 10.1
128 b-cell lymphoma 10.1
129 neuropathy 10.1
130 48,xyyy 10.1
131 temporal arteritis 10.1
132 hereditary lymphedema i 10.1
133 goiter 10.1
134 amenorrhea 10.1
135 candidiasis 10.1
136 nocardiosis 10.1
137 hepatic vascular disease 10.1
138 myocarditis 10.1
139 vein disease 10.1
140 partial deletion of the long arm of chromosome 20 10.1
141 hypertension, essential 10.1 SRC SH2B3 MIR223 KIT JAK2 FGF2
142 peripheral t-cell lymphoma 10.1
143 paroxysmal nocturnal hemoglobinuria 10.1
144 histiocytosis 10.1
145 monocytic leukemia 10.1
146 amyloidosis 10.1
147 exanthem 10.1
148 nephrotic syndrome 10.1
149 diarrhea 10.1
150 thrombocytopenia due to platelet alloimmunization 10.1
151 red cell aplasia 10.1
152 otitis media 10.1
153 tobacco addiction 10.1
154 opiate dependence 10.1
155 vascular dementia 10.1
156 down syndrome 10.1
157 lymphoma, hodgkin, classic 10.1
158 mycobacterium tuberculosis 1 10.1
159 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
160 diffuse large b-cell lymphoma 10.1
161 dermatomyositis 10.1
162 primary biliary cirrhosis 10.1
163 hyperuricemia 10.1
164 wernicke encephalopathy 10.1
165 splenic infarction 10.1
166 acute kidney failure 10.1
167 pulmonary fibrosis 10.1
168 kidney disease 10.1
169 myeloid splenomegaly 10.1
170 pik3ca-related overgrowth syndrome 10.1
171 prostate disease 10.0 MIR223 MIR146B MEG3 CDKN2B-AS1
172 azoospermia 10.0
173 hemoglobin h disease 10.0
174 withdrawal disorder 10.0
175 lymphoproliferative syndrome 10.0
176 systemic scleroderma 10.0
177 ileus 10.0
178 periostitis 10.0
179 acute monoblastic leukemia 10.0
180 encephalopathy 10.0
181 xanthomatosis 10.0
182 osteitis fibrosa 10.0
183 bone inflammation disease 10.0
184 miliary tuberculosis 10.0
185 refractory anemia with excess blasts in transformation 10.0
186 leukemia, acute monocytic 10.0
187 scleroderma, familial progressive 10.0
188 triiodothyronine receptor auxiliary protein 10.0
189 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
190 immune deficiency disease 10.0
191 langerhans cell histiocytosis 10.0
192 lymphoma, non-hodgkin, familial 10.0
193 hemophagocytic lymphohistiocytosis 10.0
194 severe congenital neutropenia 10.0
195 bone disease 10.0
196 primary hyperparathyroidism 10.0
197 patau syndrome 10.0
198 gout 10.0
199 urticaria 10.0
200 agammaglobulinemia 10.0
201 glomerulonephritis 10.0
202 pulmonary tuberculosis 10.0
203 parathyroid adenoma 10.0
204 arthritis 10.0
205 vasculitis 10.0
206 bone marrow necrosis 10.0
207 cytokine deficiency 10.0
208 granulocytopenia 10.0
209 thrombotic microangiopathy 10.0
210 mccune-albright syndrome 10.0
211 pyridoxine deficiency 10.0
212 mastocytosis, cutaneous 9.9
213 pulmonary hypertension, primary, 1 9.9
214 dowling-degos disease 1 9.9
215 werner syndrome 9.9
216 wilms tumor 5 9.9
217 alpha-thalassemia 9.9
218 psoriatic arthritis 9.9
219 angiosarcoma 9.9
220 hyperphosphatemia 9.9
221 marginal zone b-cell lymphoma 9.9
222 splenic marginal zone lymphoma 9.9
223 mucositis 9.9
224 angioimmunoblastic t-cell lymphoma 9.9
225 bacterial infectious disease 9.9
226 hydronephrosis 9.9
227 secondary hyperparathyroidism 9.9
228 hereditary spherocytosis 9.9
229 renal osteodystrophy 9.9
230 focal segmental glomerulosclerosis 9.9
231 pure red-cell aplasia 9.9
232 polyneuropathy 9.9
233 vascular disease 9.9
234 bilirubin metabolic disorder 9.9
235 antiphospholipid syndrome 9.9
236 urinary tract obstruction 9.9
237 connective tissue disease 9.9
238 plasma cell neoplasm 9.9
239 adenoma 9.9
240 juvenile rheumatoid arthritis 9.9
241 ulcerative colitis 9.9
242 evans' syndrome 9.9
243 sideroblastic anemia 9.9
244 macroglobulinemia 9.9
245 alopecia 9.9
246 1q duplications 9.9
247 homologous wasting disease 9.9
248 raynaud phenomenon 9.9
249 headache 9.9
250 tafro syndrome 9.9
251 bladder cancer 9.8
252 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative 9.8
253 asthma 9.8
254 suppression of tumorigenicity 12 9.8
255 omenn syndrome 9.8
256 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive 9.8
257 leptin deficiency or dysfunction 9.8
258 fibrous dysplasia 9.8
259 childhood acute lymphocytic leukemia 9.8
260 poems syndrome 9.8
261 fibrosarcoma 9.8
262 gastritis 9.8
263 cytomegalovirus infection 9.8
264 argyria 9.8
265 precursor t-cell acute lymphoblastic leukemia 9.8
266 breast cancer 9.8
267 pernicious anemia 9.8
268 porphyria cutanea tarda 9.8
269 rheumatoid arthritis 9.8
270 myeloperoxidase deficiency 9.8
271 reticulum cell sarcoma 9.8
272 sjogren syndrome 9.8
273 thymoma, familial 9.8
274 hemophilia a 9.8
275 ataxia and polyneuropathy, adult-onset 9.8
276 yemenite deaf-blind hypopigmentation syndrome 9.8
277 sickle cell anemia 9.8
278 pulmonary disease, chronic obstructive 9.8
279 neutrophilic dermatosis, acute febrile 9.8
280 kala-azar 1 9.8
281 gastric cancer 9.8
282 beta-thalassemia 9.8
283 juvenile arthritis 9.8
284 vitamin b12 deficiency 9.8
285 autosomal recessive disease 9.8
286 mantle cell lymphoma 9.8
287 lymphoblastic lymphoma 9.8
288 ehrlichiosis 9.8
289 osteomalacia 9.8
290 brucellosis 9.8
291 hypoparathyroidism 9.8
292 microcytic anemia 9.8
293 hemopericardium 9.8
294 cardiac tamponade 9.8
295 iron deficiency anemia 9.8
296 pericardial effusion 9.8
297 pulmonary alveolar proteinosis 9.8
298 plica syndrome 9.8
299 porphyria 9.8
300 alcoholic liver cirrhosis 9.8
301 hereditary angioedema 9.8
302 panniculitis 9.8
303 angioedema 9.8
304 lymphadenitis 9.8
305 gaucher's disease 9.8
306 cholecystitis 9.8
307 hepatitis b 9.8
308 autoimmune hepatitis 9.8
309 constipation 9.8
310 factor xiii deficiency 9.8
311 macrocytic anemia 9.8
312 sensory peripheral neuropathy 9.8
313 angiodysplasia 9.8
314 basal cell carcinoma 9.8
315 splenic disease 9.8
316 synovitis 9.8
317 scleredema adultorum 9.8
318 thymoma 9.8
319 teratoma 9.8
320 gastric adenocarcinoma 9.8
321 plasmacytoma 9.8
322 liver disease 9.8
323 hypertrichosis 9.8
324 pneumonia 9.8
325 nephrolithiasis 9.8
326 lymphopenia 9.8
327 neuroblastoma 9.8
328 end stage renal disease 9.8
329 peritonitis 9.8
330 intestinal obstruction 9.8
331 collagen disease 9.8
332 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.8
333 crohn's disease 9.8
334 leishmaniasis 9.8
335 visceral leishmaniasis 9.8
336 erythromelalgia 9.8
337 plasma cell leukemia 9.8
338 polyarteritis nodosa 9.8
339 hemophilia 9.8
340 acquired hemophilia 9.8
341 acquired hemophilia a 9.8
342 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8
343 cerebral beriberi 9.8
344 dysphagia 9.8
345 tremor 9.8
346 posttransplant acute limbic encephalitis 9.8
347 systemic autoimmune disease 9.8
348 glial tumor 9.8
349 rapidly involuting congenital hemangioma 9.8
350 acute liver failure 9.8
351 rare tumor 9.8
352 pheochromocytoma 9.8
353 meningioma, radiation-induced 9.8
354 meningioma, familial 9.8
355 adrenal gland pheochromocytoma 9.8
356 brain meningioma 9.8
357 spinal meningioma 9.8
358 dysentery 9.8
359 pericarditis 9.8
360 liver sarcoma 9.8
361 hemoglobinopathy 9.8
362 secretory meningioma 9.8
363 lymphoplasmacyte-rich meningioma 9.8
364 tubular adenocarcinoma 9.8
365 hyperthyroidism 9.8
366 toxoplasmosis 9.8
367 acquired pure red cell aplasia 9.8
368 amaurosis fugax 9.8
369 cytomegalic inclusion disease 9.8
370 hemoglobin c-beta-thalassemia syndrome 9.8
371 neurofibromatosis, type ii 9.7
372 spondyloarthropathy 1 9.7
373 leri-weill dyschondrosteosis 9.7
374 elliptocytosis 2 9.7
375 esophageal cancer 9.7
376 felty syndrome 9.7
377 hypercholesterolemia, familial, 1 9.7
378 renal cell carcinoma, nonpapillary 9.7
379 hypertriglyceridemia, familial 9.7
380 kaposi sarcoma 9.7
381 lipomatosis, multiple 9.7
382 chromosome 5q deletion syndrome 9.7
383 nondisjunction 9.7
384 myositis 9.7
385 noonan syndrome 1 9.7
386 osteoporosis 9.7
387 pelger-huet anomaly 9.7
388 prostate cancer 9.7
389 pulmonary fibrosis, idiopathic 9.7
390 retinal detachment 9.7
391 retinoblastoma 9.7
392 sarcoidosis 1 9.7
393 trichorhinophalangeal syndrome, type i 9.7
394 suppressor of tumorigenicity 3 9.7
395 abetalipoproteinemia 9.7
396 australia antigen 9.7
397 lung cancer 9.7
398 cryptorchidism, unilateral or bilateral 9.7
399 factor vii deficiency 9.7
400 gaucher disease, type i 9.7
401 ghosal hematodiaphyseal dysplasia 9.7
402 macrocephaly/megalencephaly syndrome, autosomal recessive 9.7
403 familial mediterranean fever 9.7
404 myasthenia gravis 9.7
405 ocular motor apraxia 9.7
406 hypertrophic osteoarthropathy, primary, autosomal recessive, 1 9.7
407 pyruvate kinase deficiency of red cells 9.7
408 hemophagocytic lymphohistiocytosis, familial, 1 9.7
409 revesz syndrome 9.7
410 sea-blue histiocyte disease 9.7
411 alpha-thalassemia myelodysplasia syndrome 9.7
412 thrombocytopenia with beta-thalassemia, x-linked 9.7
413 retinitis pigmentosa 11 9.7
414 stroke, ischemic 9.7
415 homocysteinemia 9.7
416 body mass index quantitative trait locus 1 9.7
417 hypereosinophilic syndrome, idiopathic 9.7
418 noonan syndrome-like disorder with loose anagen hair 1 9.7
419 juvenile myelomonocytic leukemia 9.7
420 parathyroid carcinoma 9.7
421 myocardial infarction 9.7
422 syndactyly, mesoaxial synostotic, with phalangeal reduction 9.7
423 malaria 9.7
424 bone mineral density quantitative trait locus 8 9.7
425 lung cancer susceptibility 3 9.7
426 bone mineral density quantitative trait locus 15 9.7
427 aspergillosis 9.7
428 hypertrophic osteoarthropathy, primary, autosomal recessive, 2 9.7
429 thrombocythemia 3 9.7
430 membranous nephropathy 9.7
431 human herpesvirus 8 9.7
432 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 9.7
433 steel syndrome 9.7
434 carbonic anhydrase va deficiency, hyperammonemia due to 9.7
435 takenouchi-kosaki syndrome 9.7
436 elliptocytosis 3 9.7
437 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.7
438 bacterial sepsis 9.7
439 aspiration pneumonia 9.7
440 periventricular nodular heterotopia 9.7
441 adult t-cell leukemia 9.7
442 inflammatory bowel disease 9.7
443 hypochromic microcytic anemia 9.7
444 lymphoplasmacytic lymphoma 9.7
445 metabolic acidosis 9.7
446 zollinger-ellison syndrome 9.7
447 follicular lymphoma 9.7
448 aphasia 9.7
449 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 9.7
450 colitis 9.7
451 crohn's colitis 9.7
452 crest syndrome 9.7
453 sclerosteosis 9.7
454 ptosis 9.7
455 bone resorption disease 9.7
456 hepatic veno-occlusive disease 9.7
457 urolithiasis 9.7
458 rasopathy 9.7
459 acquired von willebrand syndrome 9.7
460 castleman disease 9.7
461 endocarditis 9.7
462 secondary hypertrophic osteoarthropathy 9.7
463 nasopharyngitis 9.7
464 interstitial nephritis 9.7
465 thrombotic thrombocytopenic purpura 9.7
466 primary polycythemia 9.7
467 filariasis 9.7
468 hydrocephalus 9.7
469 oculomotor nerve paralysis 9.7
470 multicentric reticulohistiocytosis 9.7
471 visual epilepsy 9.7
472 ecthyma 9.7
473 hypertrophic cardiomyopathy 9.7
474 cryptococcosis 9.7
475 inflammatory spondylopathy 9.7
476 low compliance bladder 9.7
477 dengue disease 9.7
478 bronchopneumonia 9.7
479 von willebrand's disease 9.7
480 hepatic coma 9.7
481 leiomyoma 9.7
482 telangiectasis 9.7
483 uveitis 9.7
484 hepatic encephalopathy 9.7
485 coccidioidomycosis 9.7
486 osteopetrosis 9.7
487 hepatic infarction 9.7
488 toxic shock syndrome 9.7
489 hypothyroidism 9.7
490 papilledema 9.7
491 nodular nonsuppurative panniculitis 9.7
492 cystitis 9.7
493 retinal vein occlusion 9.7
494 islet cell tumor 9.7
495 leiomyosarcoma 9.7
496 hyperinsulinism 9.7
497 enthesopathy 9.7
498 intestinal perforation 9.7
499 hepatitis 9.7
500 motor neuron disease 9.7
501 polyclonal hypergammaglobulinemia 9.7
502 arteriosclerosis 9.7
503 acromegaly 9.7
504 central retinal vein occlusion 9.7
505 thrombophilia 9.7
506 hemangioma 9.7
507 kidney cancer 9.7
508 parasitic protozoa infectious disease 9.7
509 erythropoietin polycythemia 9.7
510 endometriosis 9.7
511 anuria 9.7
512 adenocarcinoma 9.7
513 glioblastoma multiforme 9.7
514 malignant glioma 9.7
515 interstitial lung disease 9.7
516 gallbladder cancer 9.7
517 myelitis 9.7
518 ischemia 9.7
519 spindle cell thymoma 9.7
520 thymic carcinoma 9.7
521 fibrosarcoma of bone 9.7
522 mammary paget's disease 9.7
523 cellulitis 9.7
524 linitis plastica 9.7
525 syphilis 9.7
526 myopathy 9.7
527 erdheim-chester disease 9.7
528 pustulosis of palm and sole 9.7
529 seminoma 9.7
530 familial retinoblastoma 9.7
531 indolent systemic mastocytosis 9.7
532 uremia 9.7
533 calciphylaxis 9.7
534 embryoma 9.7
535 proliferative glomerulonephritis 9.7
536 mesangial proliferative glomerulonephritis 9.7
537 elephantiasis 9.7
538 ureteral obstruction 9.7
539 gastrinoma 9.7
540 third cranial nerve disease 9.7
541 adenosine deaminase deficiency 9.7
542 posterior myocardial infarction 9.7
543 congenital hemolytic anemia 9.7
544 paraplegia 9.7
545 thyroid hyalinizing trabecular adenoma 9.7
546 spondylitis 9.7
547 t-cell lymphoblastic leukemia/lymphoma 9.7
548 thyroiditis 9.7
549 peptic ulcer disease 9.7
550 chronic kidney disease 9.7
551 septic arthritis 9.7
552 appendicitis 9.7
553 pyridoxine deficiency anemia 9.7
554 polyhydramnios 9.7
555 lung disease 9.7
556 herpes zoster 9.7
557 herpes simplex 9.7
558 hodgkin's lymphoma, lymphocytic depletion 9.7
559 neurofibromatosis 9.7
560 in situ carcinoma 9.7
561 rubella 9.7
562 psoriasis 9.7
563 splenic tuberculosis 9.7
564 exophthalmos 9.7
565 hypopituitarism 9.7
566 acute myocardial infarction 9.7
567 diabetes insipidus 9.7
568 intracranial hypertension 9.7
569 cholangitis 9.7
570 smoldering myeloma 9.7
571 stomatitis 9.7
572 sickle cell disease 9.7
573 acquired angioedema 9.7
574 acute erythroid leukemia 9.7
575 acute myeloblastic leukemia with maturation 9.7
576 anaplastic plasmacytoma 9.7
577 aquagenic pruritus 9.7
578 bowen's disease 9.7
579 chromosome 20q deletion 9.7
580 cutis verticis gyrata 9.7
581 fibrillary glomerulonephritis 9.7
582 hemangioendothelioma 9.7
583 human t-cell leukemia virus type 1 9.7
584 leukemia, t-cell, chronic 9.7
585 lymphomatoid granulomatosis 9.7
586 madelung deformity 9.7
587 mosaic trisomy 8 9.7
588 mycobacterium kansasii 9.7
589 nodular regenerative hyperplasia 9.7
590 post-transplant lymphoproliferative disease 9.7
591 posterior urethral valves 9.7
592 pseudo pelger-huet anomaly 9.7
593 pseudo-turner syndrome 9.7
594 spastic paraparesis 9.7
595 stenotrophomonas maltophilia infection 9.7
596 stevens-johnson syndrome/toxic epidermal necrolysis 9.7
597 telangiectasia macularis eruptive perstans 9.7
598 thrombasthenia 9.7
599 cryptogenic cirrhosis 9.7
600 aneurysm 9.7
601 back pain 9.7
602 hypertonia 9.7
603 hypotonia 9.7
604 megalencephaly 9.7
605 seizure disorder 9.7
606 epithelioid hemangioendothelioma 9.7
607 primary hemophagocytic lymphohistiocytosis 9.7
608 partial duplication of chromosome 1 9.7
609 ring chromosome 9.7
610 secondary pulmonary alveolar proteinosis 9.7
611 diffuse alveolar hemorrhage 9.7
612 histiocytic sarcoma 9.7
613 large granular lymphocyte leukemia 9.7
614 hepatosplenic t-cell lymphoma 9.7
615 polyploidy 9.7
616 monosomy 22 9.7
617 glomerular disease 9.7
618 overgrowth syndrome 9.7
619 intravascular large b-cell lymphoma 9.7
620 acute megakaryoblastic leukemia in down syndrome 9.7

Graphical network of the top 20 diseases related to Myelofibrosis:



Diseases related to Myelofibrosis

Symptoms & Phenotypes for Myelofibrosis

Human phenotypes related to Myelofibrosis:

58 31 (showing 39, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
2 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
3 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
4 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
5 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
6 thrombocytopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001873
7 hepatosplenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001433
8 abnormal megakaryocyte morphology 58 31 frequent (33%) Frequent (79-30%) HP:0012143
9 portal hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0001409
10 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936
11 easy fatigability 58 31 occasional (7.5%) Occasional (29-5%) HP:0003388
12 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
13 petechiae 58 31 occasional (7.5%) Occasional (29-5%) HP:0000967
14 arterial thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004420
15 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
16 pancytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001876
17 leukocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001974
18 low-grade fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0011134
19 thrombocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001894
20 extramedullary hematopoiesis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001978
21 poikilocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004447
22 ecchymosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0031364
23 bone marrow hypercellularity 58 31 occasional (7.5%) Occasional (29-5%) HP:0031020
24 flank pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0030157
25 cachexia 58 31 very rare (1%) Very rare (<4-1%) HP:0004326
26 hemangioma 58 31 very rare (1%) Very rare (<4-1%) HP:0001028
27 hematological neoplasm 58 31 very rare (1%) Very rare (<4-1%) HP:0004377
28 increased lactate dehydrogenase level 31 very rare (1%) HP:0025435
29 fever 58 31 Occasional (29-5%) HP:0001945
30 purpura 58 31 Occasional (29-5%) HP:0000979
31 abnormal bleeding 58 Occasional (29-5%)
32 abnormality of bone marrow cell morphology 58 Very frequent (99-80%)
33 abnormality of blood and blood-forming tissues 58 Frequent (79-30%)
34 myelofibrosis 31 HP:0011974
35 myeloproliferative disorder 31 HP:0005547
36 autoimmune antibody positivity 58 Excluded (0%)
37 abnormal thrombosis 58 Occasional (29-5%)
38 increased lactate dehydrogenase activity 58 Very rare (<4-1%)
39 constitutional symptom 58 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM:

56
Hematology:
myeloproliferative disease
reduced hemopoiesis
generalized bone marrow fibrosis
no hemophagocytosis

Clinical features from OMIM:

254450

MGI Mouse Phenotypes related to Myelofibrosis:

45 (showing 3, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.9 CALR EPO FGF2 GATA1 JAK2 KIT
2 hematopoietic system MP:0005397 9.73 CD177 EPO FGF2 GATA1 JAK2 KIT
3 immune system MP:0005387 9.36 CD177 EPO GATA1 JAK2 KIT MPIG6B

Drugs & Therapeutics for Myelofibrosis

Drugs for Myelofibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 321, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
2
Panobinostat Approved, Investigational Phase 4 404950-80-7 6918837
3
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
4
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
5
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
6 Trace Elements Phase 4
7 Micronutrients Phase 4
8 Vitamins Phase 4
9 Nutrients Phase 4
10 Mitogens Phase 4
11 Calcium, Dietary Phase 4
12 Endothelial Growth Factors Phase 4
13 Calciferol Phase 4
14 Angiogenesis Inducing Agents Phase 4
15 Histone Deacetylase Inhibitors Phase 4
16 Tin Fluorides Phase 4
17
Calcium Nutraceutical Phase 4 7440-70-2 271
18
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
19
Dalteparin Approved Phase 3 9005-49-6
20
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
21
Captopril Approved Phase 3 62571-86-2 44093
22
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
23
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
24
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
25
Ribavirin Approved Phase 3 36791-04-5 37542
26
Palivizumab Approved, Investigational Phase 3 188039-54-5
27
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
28
Acyclovir Approved Phase 3 59277-89-3 2022
29
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
31
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
32
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
33
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
34
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
35
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
36
Mercaptopurine Approved Phase 3 50-44-2 667490
37
Danazol Approved Phase 3 17230-88-5 28417
38
Hydroxyurea Approved Phase 3 127-07-1 3657
39
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
40
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
41
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
42
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
43
Polyestradiol phosphate Approved Phase 3 28014-46-2
44
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
45
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
46
Tyrosine Approved, Investigational, Nutraceutical Phase 2, Phase 3 60-18-4 6057
47 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
48 Anesthetics, Dissociative Phase 3
49 Neurotransmitter Agents Phase 3
50 Analgesics, Opioid Phase 3
51 Psychotropic Drugs Phase 3
52 Anti-Anxiety Agents Phase 3
53 Antipsychotic Agents Phase 3
54 Heparin, Low-Molecular-Weight Phase 3
55 Antihypertensive Agents Phase 3
56 Angiotensin-Converting Enzyme Inhibitors Phase 3
57
Hydroxyitraconazole Phase 3
58 Cytochrome P-450 CYP3A Inhibitors Phase 3
59 Excitatory Amino Acid Antagonists Phase 3
60 Narcotics Phase 3
61 Analgesics Phase 3
62 Cola Phase 3
63 valacyclovir Phase 3
64 Androgens Phase 3
65 Platelet Aggregation Inhibitors Phase 3
66 Antipyretics Phase 3
67 Analgesics, Non-Narcotic Phase 3
68 Cyclooxygenase Inhibitors Phase 3
69 Anti-Inflammatory Agents, Non-Steroidal Phase 3
70 Anesthetics Phase 3
71 Antiprotozoal Agents Phase 3
72 Antiparasitic Agents Phase 3
73 Anesthetics, General Phase 3
74 Anesthetics, Intravenous Phase 3
75 Amebicides Phase 3
76 Liposomal amphotericin B Phase 3
77 Protein Kinase Inhibitors Phase 3
78 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3
79 Estrogen Receptor Antagonists Phase 3
80 Estrogen Antagonists Phase 3
81 Estrogens Phase 3
82 Hepcidins Phase 3
83 Interferon-alpha Phase 3
84 Interferon alpha-2 Phase 3
85 glucocorticoids Phase 3
86 Janus Kinase Inhibitors Phase 3
87 interferons Phase 3
88 Estradiol 17 beta-cypionate Phase 3
89 Contraceptives, Oral Phase 3
90 Contraceptive Agents Phase 3
91 Contraceptives, Oral, Combined Phase 3
92 Estradiol 3-benzoate Phase 3
93 Norgestimate, ethinyl estradiol drug combination Phase 3
94
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
95
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
96
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
97
Zoledronic Acid Approved Phase 2 118072-93-8 68740
98
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
99
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
100
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
101
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
102
Idarubicin Approved Phase 2 58957-92-9 42890
103
tannic acid Approved Phase 1, Phase 2 1401-55-4
104
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
105
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
106
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
107
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
108
Mirabegron Approved Phase 2 223673-61-8 9865528
109
Nicotinamide Approved, Investigational Phase 2 98-92-0 936